Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 14/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | BLK | P51451 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040496 | 1.00 | FLT3 (0.42) | FLT3EIF2AK4ROCK2CYP3A4LCK | |
| SCHEMBL2034161 | 0.87 | EIF2AK4 (0.43) | FLT3EIF2AK4 | |
| SCHEMBL2033528 | 0.87 | EIF2AK4 (0.43) | FLT3EIF2AK4 | |
| SCHEMBL2033532 | 0.87 | EIF2AK4 (0.43) | FLT3EIF2AK4 | |
| SCHEMBL2037775 | 0.87 | FLT3 (0.42) | FLT3EIF2AK4ROCK2CYP3A4 | |
| SCHEMBL2037771 | 0.87 | FLT3 (0.42) | FLT3EIF2AK4ROCK2CYP3A4 | |
| SCHEMBL2035574 | 0.85 | FLT3 (0.42) | FLT3EIF2AK4 | |
| SCHEMBL2035573 | 0.85 | FLT3 (0.42) | FLT3EIF2AK4 | |
| SCHEMBL2035859 | 0.83 | EIF2AK4 (0.46) | FLT3EIF2AK4IRAK4 | |
| SCHEMBL2035861 | 0.83 | EIF2AK4 (0.46) | FLT3EIF2AK4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 21/4885EIF2AK4 211/4885ROCK2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.